Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Impact · against what's priced in

The publication of head-to-head data validating GraftAssure's clinical equivalence and superior sensitivity compared to NGS assays removes a primary technical barrier to adoption for IMDX. The news also signals a concrete path toward EU regulatory submission, expanding the company's addressable market.

IMDX+0.70

No priced-in read yet